Fabio Luciano

Dr. Fabio Luciano

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FLFabio Luciano
Fabio Luciano
LBLorenzo Bertolino
Lorenzo Bertolino
FPFabian Patauner
Fabian Patauner
FBFilomena Boccia
Filomena Boccia
RGRaffaella Gallo
Raffaella Gallo
Emanuele Durante-MangoniEmanuele Durante-Mangoni
Emanuele Durante-Mangoni
Objectives: Fosfomycin is an old antibiotic that has recently gained attention owing to its preserved activity against multidrug-resistant (MDR) bacteria. Data on its use in real life are limited. Thus, we evaluated the efficacy and safety of fosfomycin disodium in the context of our hospital clinical practice. Methods: Single-center, retrospective, observational study on 56 patients who received fosfomycin disodium from September 2016 to July 2023, focusing on clinical and microbiological outcomes and adverse events. Results: Included in this study were 56 patients. Fosfomycin disodium was administered for a median duration of 10 days [5–13.5] and was always used in combination with other antibiotics, more frequently with meropenem (16 cases, 28.6%) and colistin (11 cases, 19.6%). It was mostly used for treating pneumonia (41%), followed by bloodstream infections (19.6%), urinary tract infections (16.1%), bone infections (16.1%), and surgical site infections (7.1%). The most common isolated pathogen was Pseudomonas aeruginosa (17%), and polymicrobial infections were detected in 18 patients (32%). Among the isolated bacteria, 36 (44.4%) were MDR. The complete resolution, defined as the disappearance of symptoms, eradication of the causative microorganism, and decrease in CRP levels, was achieved in 39% of cases. During treatment, we observed electrolyte imbalances, in particular a decrease in serum potassium (0.6 mEq/L [0.3–1.1]), calcium (0.7 mEq/L [0.3–1.1]) and magnesium levels (0.3 mg/dL [0.20–0.48]), and an increase in serum sodium levels (4 mEq/dL [2–7]). Changes in potassium and sodium levels were more pronounced in patients with prior kidney dysfunction and heart failure, respectively, and in patients receiving fosfomycin diluted with saline compared with 5% glucose solution (p = 0.04). Conclusions: Fosfomycin is effective in treating complicated infections in comorbid patients when combined with other antimicrobials. During treatment, major electrolyte imbalances occur that require careful monitoring and correction, especially in patients with prior kidney disease.

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
BLB.L. Lynch
B.L. Lynch
FLFabio Luciano
Fabio Luciano
FHF. Hegarty
F. Hegarty
AKA. Killarney
A. Killarney
MMM.A. Murray
M.A. Murray
MHM.M. Hannan
M.M. Hannan

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
PDF file
FLFabio Luciano
Fabio Luciano
COC. O'Donnell
C. O'Donnell
BLB. Lynch
B. Lynch
EJE. Joyce
E. Joyce
PGP. Ging
P. Ging
MHM.M. Hannan
M.M. Hannan
Purpose Rejection and infections are leading threats in patients undergoing heart transplantation (HTx). While invasive fungal infections (IFI) have decreased due to antifungal prophylaxis and optimised immunosuppressant therapy, IFI remains the most threatening infection after HTx. We performed a single-centre retrospective study on the epidemiology of IFI post HTx. Methods All HTx were reviewed from January 2013-December 2020. In accordance with Infectious Disease Society of America (IDSA) guidelines, we looked at IFI seeking histo/cytological, molecular and microbiological findings for aspergillosis; real time PCR for Pneumocystis jirovecii pneumonia (PJP); positive cultures in sterile sites for candidiasis. We compared these findings with the occurrence of ≥ 2R cellular (ACR) and ≥ pAMR1 humoral (AMR) rejections, defined by positive endomyocardial biopsies (EMB), as stated by the International Society for Heart and Lung Transplantation (ISHLT). Appropriate parametric and non-parametric tests were used to analyse the data. Results A total of 115 patients underwent HTx from January 2013-December 2020. Median age was 57 years (IQR= 21,50), 75 (65%) male and 34 (29,6% female. Overall, 64 (55%) received a diagnosis of rejection, 57 (89%) ACR, 29 (45%) AMR and 22 (34%) had both types of rejection, occurred a median of 29 days (IQR= 62) after transplant. 15 (23%) of them had at least one episode of IFI, while 4 patients had IFI without rejection (7,8%) (p= 0,04; Fisher), totalling 26 episodes in all. The IFI episodes occurred a median of 45 days (IQR= 214) after the first episode of rejection and a median of 87 days (IQR= 242) after the transplant (p= 0,08). The most common infection was Aspergillosis with 9 episodes (60%); candidiasis was diagnosed 6 times (40%). There were 2 cases of mucormycosis (13%) and 1 case of PJP (7%). Conclusion The risk of developing IFI post HTx is considered low. In our single-centre study IFI occurred in almost a quarter of patients following a rejection episode, with aspergillosis being the most common infection. These findings support the consideration of antifungal prophylaxis after treated rejection episodes.